Cancer Clinical Trial -Merck B-21 Keynote-b21-GOG-3053

High risk for recurrent endometrial after curative intent surgery: stage I/II with myometrial invasion, non-endometrioid histology or myometrial invasion with p35 overexpression or mutation. Stage II or IVA any histology 

Drug

Carboplatin/paclitaxel, pembrolizumab, radiation

Phase

Phase II/III

Condition

Endometrial

Keywords

p35 mutation